



Notice Regarding Offer of Refunds to 340B Covered Entities for 3Q2022 – 2Q2023

Neurocrine Biosciences, Inc. (“Neurocrine”) has recently recalculated 340B Ceiling Prices for the NDC listed below for the time period of July 1, 2022 through June 30, 2023. The recalculated Ceiling Prices are the result of restatements of Medicaid pricing data that were submitted to the Centers for Medicare & Medicaid Services.

Neurocrine has asked the Health Resources and Services Administration (HRSA) to post this notice on the HRSA public website to ensure transparency to all 340B Covered Entities.

As a result of the recalculated 340B Ceiling Prices, Neurocrine has determined that a refund may be owed to 340B Covered Entities that purchased the below product during the July 1, 2022 through June 30, 2023 period.

NDC	Product Description
70370-1080-01	INGREZZA® 80MG CAPSULES

Neurocrine will use wholesaler chargeback records to calculate and automatically issue refund adjustments through the wholesalers that submitted the original sale on behalf of the 340B Covered Entities.

If a Covered Entity believes they are due a refund and is not provided this refund through its wholesaler by August 31, 2023, please contact Trade@neurocrine.com. In addition, please provide 340B ID, Quantity, Original Purchase Invoice Number, Invoice Date, and the Wholesaler the product was purchased through so that we can research your inquiry further.